Men harboring pathogenic BRCA2 variants are now advised to initiate prostate cancer screening, prostate-specific antigen (PSA) and digital rectal examination, at younger ages, given elevated risk and the propensity for aggressive tumors [15,16]. The gene discussed is KLK3; the disease is prostate carcinoma.